FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005909629> ?p ?o ?g. }

• W2005909629 endingPage "835" @default.
• W2005909629 startingPage "819" @default.
• W2005909629 abstract "Background Ivabradine, a selective inhibitor of the pacemaker current in the sinoatrial node, has shown pure heart rate (HR)-reducing effects with anti-ischemic efficacy as well as improvement in heart failure outcomes. Objective The purpose of this study was to explore pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and tolerability in healthy male Korean volunteers, as well as to compare them with PK/PD profiles of white subjects. Methods This was a randomized, double-blind, placebo-controlled Phase I study conducted in healthy male subjects. For each of the 3 dosing groups, 9 subjects were randomized to receive ivabradine and 3 to receive placebo. Subjects received a single oral dose of ivabradine 2.5, 5, or 10 mg and after a 3-day washout period, repeat doses of 2.5, 5, or 10 mg BID for 4.5 days. Blood and urine samples were collected over 72 hours during each period, and levels of ivabradine and its metabolite S18982 were determined by using validated LC-MS/MS, followed by noncompartmental PK analysis. For PD properties and tolerability, 24-hour Holter recordings were obtained: at baseline, after a single dose, after repeated doses, and after the last dose. Serial resting 12-lead ECG assessments were also performed throughout the study. Results Forty-eight subjects were enrolled, and 45 completed the study. After single doses of 2.5, 5, and 10 mg, respective mean Cmax levels of ivabradine were 9, 15, and 39 ng/mL, and mean AUC0–last values were 30, 52, and 121 ng h/mL. At steady state, mean Cmax,ss levels were 11, 19, and 42 ng/mL, reached at a median Tmax of 0.67 hour for all 3 doses. The mean AUC0–τ levels were 43, 58, and 139 ng h/mL, respectively. The PK findings were linear with dose and time. Decreases in mean HR on both the Holter recordings and ECGs were observed in all of the ivabradine groups compared with placebo. After the repeated doses, mean decreases in HR were greater than those for the single doses for the same period. Statistically significant differences were observed between the 5- and 10-mg ivabradine groups and placebo. A total of 3 adverse events were reported in 2 subjects receiving ivabradine; both fully recovered without sequelae. Conclusions Single and repeated administration of ivabradine were generally well tolerated in these healthy male Korean volunteers. Ivabradine induced significant reductions in HR, especially at doses of 5 and 10 mg. PK/PD characteristics were similar to those found in white subjects, suggesting that the dose concentration–response relationship of ivabradine is similar between Korean and white subjects." @default.
• W2005909629 created "2016-06-24" @default.
• W2005909629 creator A5003763805 @default.
• W2005909629 creator A5007426315 @default.
• W2005909629 creator A5012863228 @default.
• W2005909629 creator A5028267413 @default.
• W2005909629 creator A5045996360 @default.
• W2005909629 creator A5058329575 @default.
• W2005909629 creator A5065283669 @default.
• W2005909629 creator A5077838016 @default.
• W2005909629 creator A5085479819 @default.
• W2005909629 date "2013-06-01" @default.
• W2005909629 modified "2023-09-27" @default.
• W2005909629 title "Evaluation of Pharmacokinetic and Pharmacodynamic Profiles and Tolerability After Single (2.5, 5, or 10 mg) and Repeated (2.5, 5, or 10 mg BID for 4.5 days) Oral Administration of Ivabradine in Healthy Male Korean Volunteers" @default.
• W2005909629 cites W1579395944 @default.
• W2005909629 cites W1590249557 @default.
• W2005909629 cites W1654241318 @default.
• W2005909629 cites W1921905207 @default.
• W2005909629 cites W197537298 @default.
• W2005909629 cites W1982231896 @default.
• W2005909629 cites W2001966526 @default.
• W2005909629 cites W2005426535 @default.
• W2005909629 cites W2012221083 @default.
• W2005909629 cites W2022106651 @default.
• W2005909629 cites W2022608906 @default.
• W2005909629 cites W2035780958 @default.
• W2005909629 cites W2039138983 @default.
• W2005909629 cites W2042912309 @default.
• W2005909629 cites W2046746746 @default.
• W2005909629 cites W2055046698 @default.
• W2005909629 cites W2059730101 @default.
• W2005909629 cites W2062837386 @default.
• W2005909629 cites W2074142746 @default.
• W2005909629 cites W2080729737 @default.
• W2005909629 cites W2098708686 @default.
• W2005909629 cites W2099530998 @default.
• W2005909629 cites W2109153798 @default.
• W2005909629 cites W2129413040 @default.
• W2005909629 cites W2129882693 @default.
• W2005909629 cites W2133097604 @default.
• W2005909629 cites W2135522403 @default.
• W2005909629 cites W2136642260 @default.
• W2005909629 cites W2137470139 @default.
• W2005909629 cites W2140264662 @default.
• W2005909629 cites W2141012940 @default.
• W2005909629 cites W2144207672 @default.
• W2005909629 cites W2145270758 @default.
• W2005909629 cites W2153384140 @default.
• W2005909629 cites W2170059806 @default.
• W2005909629 cites W2170675714 @default.
• W2005909629 cites W2174842019 @default.
• W2005909629 cites W80259396 @default.
• W2005909629 doi "https://doi.org/10.1016/j.clinthera.2013.04.012" @default.
• W2005909629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23755867" @default.
• W2005909629 hasPublicationYear "2013" @default.
• W2005909629 type Work @default.
• W2005909629 sameAs 2005909629 @default.
• W2005909629 citedByCount "14" @default.
• W2005909629 countsByYear W20059096292013 @default.
• W2005909629 countsByYear W20059096292015 @default.
• W2005909629 countsByYear W20059096292016 @default.
• W2005909629 countsByYear W20059096292018 @default.
• W2005909629 countsByYear W20059096292019 @default.
• W2005909629 countsByYear W20059096292020 @default.
• W2005909629 countsByYear W20059096292021 @default.
• W2005909629 countsByYear W20059096292022 @default.
• W2005909629 crossrefType "journal-article" @default.
• W2005909629 hasAuthorship W2005909629A5003763805 @default.
• W2005909629 hasAuthorship W2005909629A5007426315 @default.
• W2005909629 hasAuthorship W2005909629A5012863228 @default.
• W2005909629 hasAuthorship W2005909629A5028267413 @default.
• W2005909629 hasAuthorship W2005909629A5045996360 @default.
• W2005909629 hasAuthorship W2005909629A5058329575 @default.
• W2005909629 hasAuthorship W2005909629A5065283669 @default.
• W2005909629 hasAuthorship W2005909629A5077838016 @default.
• W2005909629 hasAuthorship W2005909629A5085479819 @default.
• W2005909629 hasConcept C111113717 @default.
• W2005909629 hasConcept C112705442 @default.
• W2005909629 hasConcept C126322002 @default.
• W2005909629 hasConcept C142724271 @default.
• W2005909629 hasConcept C197934379 @default.
• W2005909629 hasConcept C204787440 @default.
• W2005909629 hasConcept C22979827 @default.
• W2005909629 hasConcept C27081682 @default.
• W2005909629 hasConcept C2777288759 @default.
• W2005909629 hasConcept C2777953023 @default.
• W2005909629 hasConcept C2778375690 @default.
• W2005909629 hasConcept C2779167562 @default.
• W2005909629 hasConcept C42219234 @default.
• W2005909629 hasConcept C71924100 @default.
• W2005909629 hasConcept C84393581 @default.
• W2005909629 hasConcept C98274493 @default.
• W2005909629 hasConceptScore W2005909629C111113717 @default.
• W2005909629 hasConceptScore W2005909629C112705442 @default.
• W2005909629 hasConceptScore W2005909629C126322002 @default.
• W2005909629 hasConceptScore W2005909629C142724271 @default.
• W2005909629 hasConceptScore W2005909629C197934379 @default.
• W2005909629 hasConceptScore W2005909629C204787440 @default.

• next